JM Financial sees up to 28% upside in Dr Reddy’s and Aurobindo Pharma. Should you buy?

JM Financial has given a positive forecast for two Indian pharmaceutical companies, Dr Reddy’s Laboratories and Aurobindo Pharma. The brokerage firm expects these companies to see significant earnings growth, expand their business, and launch new products, which could lead to a potential 28% increase in their stock prices over the next 12 months. This positive outlook may encourage investors to buy shares in these companies, but it's essential to weigh the potential benefits against other market factors before making a decision.

Why it matters

JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The brokerage expects strong performance from these companies.

Market impact

Transmission channels

Likely winners & losers

Explore the intelligence

MeridStreet does not reproduce source articles. The summary and analysis above are generated by MeridStreet from public headlines and its own market model; the original reporting belongs to Economic Times. For information only — not financial advice.